Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
21991
Shown on this page
12
Current sort
Recently updated
Status scope
Recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 781–792 of 21,991 matching trials with status Recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 3 Interventional Accepts healthy volunteers

Weight Gain Prevention in Adolescents and Young Adults

NCT06905626
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Qsymia 7.5 miligrams (mg)-46 mg Extended Release Capsule, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 25 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting Phase 1 Interventional

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

NCT05711615
View directory record Official record
Conditions
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NCT06706076
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
Drug
Lead sponsor
BlossomHill Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting Phase 2 Interventional

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

NCT06897475
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY3457263, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Santa Ana, California • Ocala, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting Not applicable Interventional

4D Duke Microscope Integrated Optical Coherence Tomography in a Zeiss Artevo 800

NCT07024719
View directory record Official record
Conditions
Corneal Diseases, Retinal Diseases, Ocular Diseases
Interventions
4D MIOCT integrated into a Zeiss Artevo 800
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting Not applicable Interventional

Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings

NCT06151158
View directory record Official record
Conditions
Suicide, Attempted, Suicide Ideation, Suicide, Suicide Prevention
Interventions
Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 24 Years
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
St. Petersburg, Florida • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting Phase 2 Interventional

Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury

NCT07894991
View directory record Official record
Conditions
Spinal Cord Injury, Spasticity
Interventions
Focused extracorporeal shockwave therapy, Botulinum toxin, Sham
Device · Drug · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting Phase 3 Interventional

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

NCT07881458
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
eloralintide and tirzepatide, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
25
States / cities
Tucson, Arizona • Los Alamitos, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting Phase 3 Interventional

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

NCT07223593
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Gilbert, Arizona • Surprise, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting Phase 2 Interventional

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

NCT07673627
View directory record Official record
Conditions
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG
Interventions
Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
Biological · Other · Combination Product
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Carlsbad, California • Miami, Florida • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting Phase 1 Interventional

PET Imaging of the sigma1 Receptor in Healthy Adults

NCT07915323
View directory record Official record
Conditions
Healthy Control Subjects
Interventions
(S)-[18F] FBFP or (R)-[18F]FBFP
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST
Recruiting No phase listed Observational

Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions

NCT06476678
View directory record Official record
Conditions
Esophageal Neoplasm, Esophageal Polyp, Endoscopic Submucosal Dissection, Bipolar Electrocautery
Interventions
Speedboat™ Ultraslim
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:46 PM EST